Sign in
Taking people in United StatesPhase 1

The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)

Key facts

Who runs it
Yale University
Where
New Haven, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 1
People taking part
63 people, planned
Started
4 Aug 2025
Expected to end
1 Aug 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • 0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion
  • 0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion
  • 25 mg Diphenhydramine (5 min) + Normal Saline
Record updated
10 September 2026

Who can take part

Age
21 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (4)Hide the full registry criteria

Who can take part

  • Diagnostic and Statistical Manual of Mental Disorders-5th edition (DSM-5) diagnosis of Alcohol Use Disorder
  • Medically healthy
  • Ability to provide consent

Who cannot take part

  • Unstable medical conditions

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Alcohol-related disorders or alcohol use

This trial is currently available in United States.

  • Connecticut Mental Health CenterNew Haven, United StatesContact: Anahita Bassir Nia, MDTaking people

About the trial

What the trial wants to find out

This proposed study is a double-blind, randomized, placebo-controlled, parallel-group, laboratory study to determine the effects of DMT, plus psychotherapy, on Alcohol Use Disorder.

The 3 groups in the trial

  • Group 1Existing treatment, for comparison

    Bolus of 0.3mg/kg/min DMT (5min) + Normal Saline infusion (60 min)

    Treatment: 0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion

  • Group 2Existing treatment, for comparison

    Bolus of 0.2 mg/kg/min DMT (5 min) + 0.01mg/kg/min infusion (60 min)

    Treatment: 0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion

  • Group 3Placebo, for comparison

    Bolus of 25 mg Diphenhydramine (5 min) + Normal Saline infusion (60 min)

    Treatment: 25 mg Diphenhydramine (5 min) + Normal Saline

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT06070649, who can take part
Record updated
10 September 2026